Poster Downloads_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

top

Please input keywords

EN

Management team

Social Responsibility

Antibody Assets

Project Integrum

Antibody discovery platforms

Clinical pipeline

Preclinical pipeline

Humanized animal models

KO mouse models

Immunodeficient mice/rats

Disease mouse models

Pharmacology Service

Therapeutic area

Types of services

By technologies

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Microbial detection

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Stock Information

Financial Reports

Listing Documents

Announcements & Notices

Corporate Governance

Investor Calendar

Poster Downloads

Media Center

Poster Downloads

Brochure

AACR 2022: 1C3, a Novel Non-blocking Anti-human TNFR2 Antibody Generated From RenMice, Exhibits Promising Anti-tumor Activity and Safety in Syngeneic Tumor Models in Humanized TNFR2 Mice

AACR 2022: Generation of TCR-mimic fully human antibodies against HLA-antigen-peptide complexes using HLA transgenic RenMice

AACR 2022: YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy

A Novel PD1-CD40 Bispecific Antibody YH008 Induces Potent Anti-tumor Activity in-vivo by PD1 Dependent Activation of CD40 Signaling

SIGLEC15 humanized knock-in mice are a powerful tool to evaluate new therapies for cancer and osteoporosis

Humanized CCR8 Mouse Model Provides A Translational Tool For Anti-Human CCR8 Antibody Drug Development

Humanized B-hC5AR1 mouse model for evaluation of anti-C5AR1 mAb in vivo efficacy

Humanized IL6/hIL6R mouse model supports the evaluation of therapeutic drug candidates targeting human IL6 and IL6 receptor

Anti-GCGR in vivo efficacy evaluated in a new humanized hGCGR mouse model

1 … 9 10 11 12 13 … 15